Pneumocystis Species

Mandell, Douglas, and Bennett's Principles and Practice of Infectious Diseases

Volumn 2, Issue , 2014, Pages 3016-3030.e4

  Walzer, Peter D ^a,b   Smulian, A George ^c,d   Miller, Robert F ^e,f,g  

^a UNIVERSITY OF CINCINNATI   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^d UNIVERSITY OF CINCINNATI MEDICAL CENTER   (United States)

^e LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

^f CENTRAL AND NORTH WEST LONDON NHS FOUNDATION TRUST   (United Kingdom)

^g UNIVERSITY COLLEGE LONDON HOSPITALS   (United Kingdom)

Author keywords

AIDS; Chemoprophylaxis; Colonization; Dapsone; Diagnosis; HIV; Medical immunosuppression; P. jirovecii; Pathogenesis; PCP; Pneumocystis pneumonia; Trimethoprim sulfamethoxazole

Indexed keywords

EID: 84944555946     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4557-4801-3.00271-X     Document Type: Chapter

References (387)

1. Thomas CF, Limper AH Current insights into the biology and pathogenesis of Pneumocystis pneumonia. Nat Rev Microbiol 2007, 5:298-308.
2. Cisse OH, Pagni M, Hauser PM De novo assembly of the Pneumocystis jirovecii genome from a single bronchoalveolar lavage fluid specimen from a patient. MBio 2012, 4:e00428-e00512.
3. Morris A, Norris KA Colonization by Pneumocystis jirovecii and its role in disease. Clin Microbiol Rev 2012, 25:297-317.
4. Pneumocystis Genome Project Available at, Accessed April 15, 2014. http://pgp.cchmc.org/.
5. Broad Institute of Harvard and MIT Pneumocystis murina Sequencing Project Available at, Accessed April 15, 2014. http://www.broadinstitute.org/science/projects/fungal-genome-initiative/current-fgi-sequence-projects.
6. Sesterhenn TM, Slaven BE, Keely SP, et al. Sequence and structure of the linear mitochondrial genome of Pneumocystis carinii. Mol Genet Genomics 2010, 283:63-72.
7. Ma L, Huang DW, Cuomo CA, et al. Sequencing and characterization of the complete mitochondrial genomes of three Pneumocystis species provide new insights into divergence between human and rodent Pneumocystis. FASEB J 2013, 27:1962-1972.
8. Redhead SA, Cushion MT, Frenkel JK, et al. Pneumocystis and Trypanosoma cruzi: nomenclature and typifications. J Eukaryot Microbiol 2006, 53:2-11.
9. Stringer JR, Beard CB, Miller RF, Wakefield AE A new name (Pneumocystis jiroveci) for Pneumocystis from humans. Emerg Infect Dis 2002, 8:891-896.
10. Sloand E, Laughon B, Armstrong M, et al. The challenge of Pneumocystis carinii culture. J Eukaryot Microbiol 1993, 40:188-195.
11. Cushion MT, Collins MS, Linke MJ Biofilm formation by Pneumocystis spp. Eukaryot Cell 2009, 8:197-206.
12. Cushion MT, Collins MS Susceptibility of Pneumocystis to echinocandins in suspension and biofilm cultures. Antimicrob Agents Chemother 2011, 55:4513-4518.
13. Cushion MT Are members of the fungal genus pneumocystis (a) commensals; (b) opportunists; (c) pathogens; or (d) all of the above?. PLoS Pathog 2010, 6:e1001009.
14. Burgess JW, Kottom TJ, Limper AH Pneumocystis carinii exhibits a conserved meiotic control pathway. Infect Immun 2008, 76:417-425.
15. Kutty G, Achaz G, Maldarelli F, et al. Characterization of the meiosis-specific recombinase Dmc1 of Pneumocystis. J Infect Dis 2010, 202:1920-1929.
16. Cushion MT, Linke MJ, Ashbaugh A, et al. Echinocandin treatment of Pneumocystis pneumonia in rodent models depletes cysts leaving trophic burdens that cannot transmit the infection. PLoS One 2010, 5:e8524.
17. Schmatz DM, Powles M, McFadden DC, et al. Treatment and prevention of Pneumocystis carinii pneumonia and further elucidation of the P. carinii life cycle with 1,3-beta-glucan synthesis inhibitor L-671,329. J Protozool 1991, 38:151S-153S.
18. Kaneshiro ES Sterol metabolism in the opportunistic pathogen Pneumocystis: advances and new insights. Lipids 2004, 39:753-761.
19. Kaneshiro ES Pneumocystis carinii pneumonia: the status of Pneumocystis biochemistry. Int J Parasitol 1998, 28:65-84.
20. Hauser PM, Burdet FX, Cisse OH, et al. Comparative genomics suggests that the fungal pathogen Pneumocystis is an obligate parasite scavenging amino acids from its host's lungs. PLoS One 2010, 5:e15152.
21. Cushion MT, Smulian AG, Slaven BE, et al. Transcriptome of Pneumocystis carinii during fulminate infection: carbohydrate metabolism and the concept of a compatible parasite. PLoS One 2007, 2:e423.
22. De Stefano JA, Myers JD, Du Pont D, et al. Cell wall antigens of Pneumocystis carinii trophozoites and cysts: purification and carbohydrate analysis of these glycoproteins. J Eukaryot Microbiol 1998, 45:334-343.
23. Villegas LR, Kottom TJ, Limper AH Chitinases in Pneumocystis carinii pneumonia. Med Microbiol Immunol 2012, 201:337-348.
24. Porollo A, Meller J, Joshi Y, et al. Analysis of current antifungal agents and their targets within the Pneumocystis carinii genome. Curr Drug Targets 2012, 13:1575-1585.
25. Stringer JR Antigenic variation in pneumocystis. J Eukaryot Microbiol 2007, 54:8-13.
26. Linke MJ, Sunkin SM, Andrews RP, et al. Expression, structure, and location of epitopes of the major surface glycoprotein of Pneumocystis carinii f. sp. carinii. Clin Diagn Lab Immunol 1998, 5:50-57.
27. Gigliotti F, Hughes WT Passive immunoprophylaxis with specific monoclonal antibody confers partial protection against Pneumocystis carinii pneumonitis in animal models. J Clin Invest 1988, 81:1666-1668.
28. Theus SA, Walzer PD Adoptive transfer of specific lymphocyte populations sensitized to the major surface glycoprotein of Pneumocystis carinii decreases organism burden while increasing survival rate in the rat. J Eukaryot Microbiol 1997, 44:23S-24S.
29. Theus SA, Smulian AG, Steele P, et al. Immunization with the major surface glycoprotein of Pneumocystis carinii elicits a protective response. Vaccine 1998, 16:1149-1157.
30. Pottratz ST, Paulsrud J, Smith JS, Martin WJ Pneumocystis carinii attachment to cultured lung cells by Pneumocystis gp 120, a fibronectin binding protein. J Clin Invest 1991, 88:403-407.
31. Ezekowitz RA, Williams DJ, Koziel H, et al. Uptake of Pneumocystis carinii mediated by the macrophage mannose receptor. Nature 1991, 351:155-158.
32. Kottom TJ, Kennedy CC, Limper AH Pneumocystis PCINT1, a molecule with integrin-like features that mediates organism adhesion to fibronectin. Mol Microbiol 2008, 67:747-761.
33. Limper AH, Standing JE, Hoffman OA, et al. Vitronectin binds to Pneumocystis carinii and mediates organism attachment to cultured lung epithelial cells. Infect Immun 1993, 61:4302-4309.
34. McCormack FX, Festa AL, Andrews RP, et al. The carbohydrate recognition domain of surfactant protein A mediates binding to the major surface glycoprotein of Pneumocystis carinii. Biochemistry 1997, 36:8092-8099.
35. O'Riordan DM, Standing JE, Kwon KY, et al. Surfactant protein D interacts with Pneumocystis carinii and mediates organism adherence to alveolar macrophages. J Clin Invest 1995, 95:2699-2710.
36. Bishop LR, Helman D, Kovacs JA Discordant antibody and cellular responses to Pneumocystis major surface glycoprotein variants in mice. BMC Immunol 2012, 13:39.
37. Kutty G, Ma L, Kovacs JA Characterization of the expression site of the major surface glycoprotein of human-derived Pneumocystis carinii. Mol Microbiol 2001, 42:183-193.
38. Daly KR, Koch JV, Shire NJ, et al. Human immunodeficiency virus-infected patients with prior Pneumocystis pneumonia exhibit increased serologic reactivity to several major surface glycoprotein clones. Clin Vaccine Immunol 2006, 13:1071-1078.
39. Walzer PD, Djawe K, Levin L, et al. Long-term serologic responses to the Pneumocystis jirovecii major surface glycoprotein in HIV-positive individuals with and without P. jirovecii infection. J Infect Dis 2009, 199:1335-1344.
40. Daly K, Koch J, Respaldiza N, et al. Geographical variation in serological responses to recombinant Pneumocystis jirovecii major surface glycoprotein antigens. Clin Microbiol Infect 2009, 15:937-942.
41. Tipirneni R, Daly KR, Jarlsberg LG, et al. Healthcare worker occupation and immune response to Pneumocystis jirovecii. Emerg Infect Dis 2009, 15:1590-1597.
42. Schaffzin JK, Sunkin SM, Stringer JR A new family of Pneumocystis carinii genes related to those encoding the major surface glycoprotein. Curr Genet 1999, 35:134-143.
43. Kutty G, Kovacs JA A single-copy gene encodes Kex1, a serine endoprotease of Pneumocystis jiroveci. Infect Immun 2003, 71:571-574.
44. Smulian AG, Stringer JR, Linke MJ, Walzer PD Isolation and characterization of a recombinant antigen of Pneumocystis carinii. Infect Immun 1992, 60:907-915.
45. Smulian AG, Sullivan DW, Theus SA Immunization with recombinant Pneumocystis carinii p55 antigen provides partial protection against infection: characterization of epitope recognition associated with immunization. Microbes Infect 2000, 2:127-136.
46. Feng Y, Guo S, Jiang T, et al. Active immunization against Pneumocystis carinii with p55-v3 DNA vaccine in rats. Can J Microbiol 2011, 57:375-381.
47. Ma L, Kutty G, Jia Q, Kovacs JA Characterization of variants of the gene encoding the p55 antigen in Pneumocystis from rats and mice. J Med Microbiol 2003, 52:955-960.
48. Walzer PD Immunological features of Pneumocystis carinii infection in humans. Clin Diagn Lab Immunol 1999, 6:149-155.
49. Montes-Cano MA, Chabe M, Fontillon-Alberdi M, et al. Vertical transmission of Pneumocystis jirovecii in humans. Emerg Infect Dis 2009, 15:125-127.
50. Vargas SL, Hughes WT, Santolaya ME, et al. Search for primary infection by Pneumocystis carinii in a cohort of normal, healthy infants. Clin Infect Dis 2001, 32:855-861.
51. Larsen HH, von Linstow ML, Lundgren B, et al. Primary Pneumocystis infection in infants hospitalized with acute respiratory tract infection. Emerg Infect Dis 2007, 13:66-72.
52. Peglow SL, Smulian AG, Linke MJ, et al. Serologic responses to Pneumocystis carinii antigens in health and disease. J Infect Dis 1990, 161:296-306.
53. Vargas SL, Ponce CA, Luchsinger V, et al. Detection of Pneumocystis carinii f. sp. hominis and viruses in presumably immunocompetent infants who died in the hospital or in the community. J Infect Dis 2005, 191:122-126.
54. Hernandez D, Rodriguez N, Martinez C, et al. Leishmania braziliensis causing visceral leishmaniasis in a patient with human immunodeficiency virus infection, identified with the aid of the polymerase chain reaction. Trans R Soc Trop Med Hyg 1993, 87:627-628.
55. Linke MJ, Ashbaugh AD, Demland JA, Walzer PD Pneumocystis murina colonization in immunocompetent surfactant protein A deficient mice following environmental exposure. Respir Res 2009, 10:10.
56. Demanche C, Wanert F, Barthelemy M, et al. Molecular and serological evidence of Pneumocystis circulation in a social organization of healthy macaques (Macaca fascicularis). Microbiology 2005, 151:3117-3125.
57. Davis JL, Welsh DA, Beard CB, et al. Pneumocystis colonisation is common among hospitalised HIV infected patients with non-Pneumocystis pneumonia. Thorax 2008, 63:329-334.
58. Shipley TW, Kling HM, Morris, et al. Persistent Pneumocystis colonization leads to the development of chronic obstructive pulmonary disease in a non human primate model of AIDS. J Infect Dis 2010, 202:302-312.
59. Masur H, Michelis MA, Greene JB, et al. An outbreak of community-acquired Pneumocystis carinii pneumonia: initial manifestation of cellular immune dysfunction. N Engl J Med 1981, 305:1431-1438.
60. Miller RF, Huang L, Walzer PD Pneumocystis pneumonia associated with human immunodeficiency virus. Clin Chest Med 2013, 34:229-241.
61. Robbins JB, Miller RH, Arean VM, Pearson HA Successful treatment of Pneumocystis carinii pneumonitis in a patient with congenital agammaglobinemia. N Engl J Med 1965, 272:708-713.
62. Samuel CM, Whitelaw A, Corcoran C, et al. Improved detection of Pneumocystis jirovecii in upper and lower respiratory tract specimens from children with suspected Pneumocystis pneumonia using real-time PCR: a prospective study. BMC Infect Dis 2011, 11:329.
63. Matsumura Y, Shindo Y, Iinuma Y, et al. Clinical characteristics of Pneumocystis pneumonia in non-HIV patients and prognostic factors including microbiological genotypes. BMC Infect Dis 2011, 11:76.
64. de Boer MG, Kroon FP, le Cessie S, et al. Risk factors for Pneumocystis jirovecii pneumonia in kidney transplant recipients and appraisal of strategies for selective use of chemoprophylaxis. Transpl Infect Dis 2011, 13:559-569.
65. Siegel JD, Rhinehart E, Jackson M, et al. 2007 Guideline for isolation precautions: preventing transmission of infectious agents in health care settings. Am J Infect Control 2007, 35:S65-164.
66. Walzer P The ecology of Pneumocystis: perspectives, recollections, and future research opportunities. J Eukaryot Microbiol 2013, 60:634-645.
67. Navin TR, Rimland D, Lennox JL, et al. Risk factors for community-acquired pneumonia among persons infected with human immunodeficiency virus. J Infect Dis 2000, 181:158-164.
68. Dohn MN, White ML, Vigdorth EM, et al. Geographic clustering of Pneumocystis carinii pneumonia in patients with HIV infection. Am J Respir Crit Care Med 2000, 162:1617-1621.
69. Morris AM, Swanson M, Ha H, Huang L Geographic distribution of human immunodeficiency virus-associated Pneumocystis carinii pneumonia in San Francisco. Am J Respir Crit Care Med 2000, 162:1622-1626.
70. Miller RF, Evans HE, Copas AJ, Cassell JA Climate and genotypes of Pneumocystis jirovecii. Clin Microbiol Infect 2007, 13:445-448.
71. Djawe K, Levin L, Swartzman A, et al. Environmental risk factors for Pneumocystis pneumonia hospitalizations in HIV patients. Clin Infect Dis 2013, 56:74-81.
72. Walzer PD, Kim CK, Linke MJ, et al. Outbreaks of Pneumocystis carinii pneumonia in colonies of immunodeficient mice. Infect Immun 1989, 57:62-70.
73. Icenhour CR, Rebholz SL, Collins MS, Cushion MT Widespread occurrence of Pneumocystis carinii in commercial rat colonies detected using targeted PCR and oral swabs. J Clin Microbiol 2001, 39:3437-3441.
74. de Boer MG, de Fijter JW, Kroon FP Outbreaks and clustering of Pneumocystis pneumonia in kidney transplant recipients: a systematic review. Med Mycol 2011, 49:673-680.
75. Choukri F, Menotti J, Sarfati C, et al. Quantification and spread of Pneumocystis jirovecii in the surrounding air of patients with Pneumocystis pneumonia. Clin Infect Dis 2010, 51:259-265.
76. Djawe K, Daly KR, Vargas SL, et al. Seroepidemiological study of Pneumocystis jirovecii infection in healthy infants in Chile using recombinant fragments of the P. jirovecii major surface glycoprotein. Int J Infect Dis 2010, 14:e1060-e1066.
77. Djawe K, Huang L, Daly KR, et al. Serum antibody levels to the Pneumocystis jirovecii major surface glycoprotein in the diagnosis of P. jirovecii pneumonia in HIV+ patients. PLoS One 2010, 5:e14259.
78. Gingo MR, Lucht L, Daly KR, et al. Serologic responses to pneumocystis proteins in HIV patients with and without Pneumocystis jirovecii pneumonia. J Acquir Immune Defic Syndr 2011, 57:190-196.
79. Blount RJ, Jarlsberg LG, Daly KR, et al. Serologic responses to recombinant Pneumocystis jirovecii major surface glycoprotein among Ugandan patients with respiratory symptoms. PLoS One 2012, 7:e51545.
80. Walzer PD, Kim CK, Cushion MT Pneumocystis carinii. Parasitic Infection in the Compromised Host 1989, 83-178. Marcel Dekker, New York. P.D. Walzer, R.M. Genta (Eds.).
81. Pottratz ST, Weir AL Attachment of Pneumocystis carinii to primary cultures of rat alveolar epithelial cells. Exp Cell Res 1995, 221:357-362.
82. Kottom TJ, Kohler JR, Thomas CF, et al. Lung epithelial cells and extracellular matrix components induce expression of Pneumocystis carinii STE20, a gene complementing the mating and pseudohyphal growth defects of STE20 mutant yeast. Infect Immun 2003, 71:6463-6471.
83. Koziel H, Kim S, Reardon C, et al. Enhanced in vivo human immunodeficiency virus-1 replication in the lungs of human immunodeficiency virus-infected persons with Pneumocystis carinii pneumonia. Am J Respir Crit Care Med 1999, 160:2048-2055.
84. Limper AH, Edens M, Anders RA, Leof EB Pneumocystis carinii inhibits cyclin-dependent kinase activity in lung epithelial cells. J Clin Invest 1998, 101:1148-1155.
85. Yu ML, Limper AH Pneumocystis carinii induces ICAM-1 expression in lung epithelial cells through a TNF-alpha-mediated mechanism. Am J Physiol 1997, 273:L1103-L1111.
86. Linke MJ, Harris CE, Korfhagen TR, et al. Immunosuppressed surfactant protein A-deficient mice have increased susceptibility to Pneumocystis carinii infection. J Infect Dis 2001, 183:943-952.
87. Atochina EN, Gow AJ, Beck JM, et al. Delayed clearance of Pneumocystis carinii infection, increased inflammation, and altered nitric oxide metabolism in lungs of surfactant protein-D knockout mice. J Infect Dis 2004, 189:1528-1539.
88. Rapaka RR, Ricks DM, Alcorn JF, et al. Conserved natural IgM antibodies mediate innate and adaptive immunity against the opportunistic fungus Pneumocystis murina. J Exp Med 2010, 207:2907-2919.
89. Martin-Garrido I, Carmona EM, Specks U, Limper AH Pneumocystis pneumonia in patients treated with rituximab. Chest 2013, 144:258-265.
90. Kling HM, Shipley TW, Patil SP, et al. Relationship of Pneumocystis jiroveci humoral immunity to prevention of colonization and chronic obstructive pulmonary disease in a primate model of HIV infection. Infect Immun 2010, 78:4320-4330.
91. Harmsen AG, Chen W, Gigliotti F Active immunity to Pneumocystis carinii reinfection in T-cell-depleted mice. Infect Immun 1995, 63:2391-2395.
92. Garvy BA, Wiley JA, Gigliotti F, Harmsen AG Protection against Pneumocystis carinii pneumonia by antibodies generated from either T helper 1 or T helper 2 responses. Infect Immun 1997, 65:5052-5056.
93. Zheng M, Ramsay AJ, Robichaux MB, et al. CD4+ T cell-independent DNA vaccination against opportunistic infections. J Clin Invest 2005, 115:3536-3544.
94. Zheng M, Rapaka RR, Yu AC, et al. Role of interleukin-23-dependent antifungal immune responses in dendritic cell-vaccinated mice. Infect Immun 2011, 79:3778-3783.
95. Lund FE, Hollifield M, Schuer K, et al. B cells are required for generation of protective effector and memory CD4 cells in response to Pneumocystis lung infection. J Immunol 2006, 176:6147-6154.
96. Moir S, Fauci AS Pathogenic mechanisms of B-lymphocyte dysfunction in HIV disease. J Allergy Clin Immunol 2008, 122:12-19.
97. Laursen AL, Jensen BN, Andersen PL Local antibodies against Pneumocystis carinii in bronchoalveolar lavage fluid. Eur Respir J 1994, 7:679-685.
98. Jalil A, Moja P, Lambert C, et al. Decreased production of local immunoglobulin A to Pneumocystis carinii in bronchoalveolar lavage fluid from human immunodeficiency virus-positive patients. Infect Immun 2000, 68:1054-1060.
99. Furuta T, Fujita M, Machii K, et al. Fatal spontaneous pneumocystosis in nude rats. Lab Anim Sci 1993, 43:551-556.
100. Shellito J, Suzara VV, Blumenfeld W, et al. A new model of Pneumocystis carinii infection in mice selectively depleted of helper T lymphocytes. J Clin Invest 1990, 85:1686-1693.
101. Theus SA, Andrews RP, Steele P, Walzer PD Adoptive transfer of lymphocytes sensitized to the major surface glycoprotein of Pneumocystis carinii confers protection in the rat. J Clin Invest 1995, 95:2587-2593.
102. Harmsen AG, Stankiewicz M Requirement for CD4+ cells in resistance to Pneumocystis carinii pneumonia in mice. J Exp Med 1990, 172:937-945.
103. Steele C, Zheng M, Young E, et al. Increased host resistance against Pneumocystis carinii pneumonia in gammadelta T-cell-deficient mice: protective role of gamma interferon and CD8(+) T cells. Infect Immun 2002, 70:5208-5215.
104. Kolls JK, Habetz S, Shean MK, et al. IFN-gamma and CD8+ T cells restore host defenses against Pneumocystis carinii in mice depleted of CD4+ T cells. J Immunol 1999, 162:2890-2894.
105. Wiley JA, Harmsen AG CD40 ligand is required for resolution of Pneumocystis carinii pneumonia in mice. J Immunol 1995, 155:3525-3529.
106. Beck JM, Blackmon MB, Rose CM, et al. T cell costimulatory molecule function determines susceptibility to infection with Pneumocystis carinii in mice. J Immunol 2003, 171:1969-1977.
107. McAllister F, Steele C, Zheng M, et al. In vitro effector activity of Pneumocystis murina-specific T-cytotoxic-1 CD8+ T cells: role of granulocyte-macrophage colony-stimulating factor. Infect Immun 2005, 73:7450-7457.
108. Levy J, Espanol-Boren T, Thomas C, et al. Clinical spectrum of X-linked hyper-IgM syndrome. J Pediatr 1997, 131:47-54.
109. Garvy BA, Qureshi MH Delayed inflammatory response to Pneumocystis carinii infection in neonatal mice is due to an inadequate lung environment. J Immunol 2000, 165:6480-6486.
110. Qureshi MH, Garvy BA Neonatal T cells in an adult lung environment are competent to resolve Pneumocystis carinii pneumonia. J Immunol 2001, 166:5704-5711.
111. Phair J, Munoz A, Detels R, et al. The risk of Pneumocystis carinii pneumonia among men infected with human immunodeficiency virus type 1. Multicenter AIDS Cohort Study Group. N Engl J Med 1990, 322:161-165.
112. Kulke MH, Vance EA Pneumocystis carinii pneumonia in patients receiving chemotherapy for breast cancer. Clin Infect Dis 1997, 25:215-218.
113. + T-lymphocytopenia Task Force. N Engl J Med 1993, 328:373-379.
114. + T-lymphocyte counts during Pneumocystis carinii pneumonia in immunocompromised patients without HIV infection. Chest 2000, 118:712-720.
115. Agostini C, Adami F, Poulter LW, et al. Role of bronchoalveolar lavage in predicting survival of patients with human immunodeficiency virus infection. Am J Respir Crit Care Med 1997, 156:1501-1507.
116. Iriart X, Witkowski B, Cassaing S, et al. Alveolar and blood T lymphocyte profiles in Pneumocystis jirovecii-positive patients: effects of HIV status. J Infect Dis 2011, 204:544-553.
117. Carmona EM, Limper AH Update on the diagnosis and treatment of Pneumocystis pneumonia. Ther Adv Respir Dis 2011, 5:41-59.
118. Reid AB, Chen SC, Worth LJ Pneumocystis jirovecii pneumonia in non-HIV-infected patients: new risks and diagnostic tools. Curr Opin Infect Dis 2011, 24:534-544.
119. Hugle B, Solomon M, Harvey E, et al. Pneumocystis jiroveci pneumonia following rituximab treatment in Wegener's granulomatosis. Arthritis Care Res (Hoboken) 2010, 62:1661-1664.
120. Sepkowitz KA Opportunistic infections in patients with and patients without acquired immunodeficiency syndrome. Clin Infect Dis 2002, 34:1098-1107.
121. Yale SH, Limper AH Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illness and prior corticosteroid therapy. Mayo Clin Proc 1996, 71:5-13.
122. Godeau B, Coutant-Perronne V, Le Thi Huong D, et al. Pneumocystis carinii pneumonia in the course of connective tissue disease: report of 34 cases. J Rheumatol 1994, 21:246-251.
123. Graham BS, Tucker WS Opportunistic infections in endogenous Cushing's syndrome. Ann Intern Med 1984, 101:334-338.
124. Abernathy-Carver KJ, Fan LL, Boguniewicz M, et al. Legionella and Pneumocystis pneumonias in asthmatic children on high doses of systemic steroids. Pediatr Pulmonol 1994, 18:135-138.
125. Limper AH, Hoyte JS, Standing JE The role of alveolar macrophages in Pneumocystis carinii degradation and clearance from the lung. J Clin Invest 1997, 99:2110-2117.
126. Hanano R, Kaufmann SH Activation of pulmonary macrophages is not sufficient for in vivo containment of Pneumocystis carinii. J Eukaryot Microbiol 1997, 44:17S.
127. Steele C, Marrero L, Swain S, et al. Alveolar macrophage-mediated killing of Pneumocystis carinii f. sp. muris involves molecular recognition by the Dectin-1 beta-glucan receptor. J Exp Med 2003, 198:1677-1688.
128. Zhang C, Wang SH, Lasbury ME, et al. Toll-like receptor 2 mediates alveolar macrophage response to Pneumocystis murina. Infect Immun 2006, 74:1857-1864.
129. Ding K, Shibui A, Wang Y, et al. Impaired recognition by Toll-like receptor 4 is responsible for exacerbated murine Pneumocystis pneumonia. Microbes Infect 2005, 7:195-203.
130. Vassallo R, Kottom TJ, Standing JE, Limper AH Vitronectin and fibronectin function as glucan binding proteins augmenting macrophage responses to Pneumocystis carinii. Am J Respir Cell Mol Biol 2001, 25:203-211.
131. Vassallo R, Standing JE, Limper AH Isolated Pneumocystis carinii cell wall glucan provokes lower respiratory tract inflammatory responses. J Immunol 2000, 164:3755-3763.
132. Laursen AL, Moller B, Rungby J, et al. Pneumocystis carinii-induced activation of the respiratory burst in human monocytes and macrophages. Clin Exp Immunol 1994, 98:196-202.
133. Lasbury ME, Merali S, Durant PJ, et al. Polyamine-mediated apoptosis of alveolar macrophages during Pneumocystis pneumonia. J Biol Chem 2007, 282:11009-11020.
134. Kurkjian C, Hollifield M, Lines JL, et al. Alveolar macrophages in neonatal mice are inherently unresponsive to Pneumocystis murina infection. Infect Immun 2012, 80:2835-2846.
135. Zhang C, Wang SH, Liao CP, et al. Downregulation of PU.1 leads to decreased expression of Dectin-1 in alveolar macrophages during Pneumocystis pneumonia. Infect Immun 2010, 78:1058-1065.
136. Inoue M, Moriwaki Y, Arikawa T, et al. Cutting edge: critical role of intracellular osteopontin in antifungal innate immune responses. J Immunol 2011, 186:19-23.
137. Kandil O, Fishman JA, Koziel H, et al. Human immunodeficiency virus type 1 infection of human macrophages modulates the cytokine response to Pneumocystis carinii. Infect Immun 1994, 62:644-650.
138. Koziel H, Eichbaum Q, Kruskal BA, et al. Reduced binding and phagocytosis of Pneumocystis carinii by alveolar macrophages from persons infected with HIV-1 correlates with mannose receptor downregulation. J Clin Invest 1998, 102:1332-1344.
139. Fraser IP, Takahashi K, Koziel H, et al. Pneumocystis carinii enhances soluble mannose receptor production by macrophages. Microbes Infect 2000, 2:1305-1310.
140. Stehle SE, Rogers RA, Harmsen AG, Ezekowitz RA A soluble mannose receptor immunoadhesin enhances phagocytosis of Pneumocystis carinii by human polymorphonuclear leukocytes in vitro. Scand J Immunol 2000, 52:131-137.
141. Carmona EM, Lamont JD, Xue A, et al. Pneumocystis cell wall beta-glucan stimulates calcium-dependent signaling of IL-8 secretion by human airway epithelial cells. Respir Res 2010, 11:95.
142. Evans SE, Kottom TJ, Pagano RE, Limper AH Primary alveolar epithelial cell surface membrane microdomain function is required for Pneumocystis beta-glucan-induced inflammatory responses. Innate Immun 2012, 18:709-716.
143. Carmona EM, Kottom TJ, Hebrink DM, et al. Glycosphingolipids mediate pneumocystis cell wall beta-glucan activation of the IL-23/IL-17 axis in human dendritic cells. Am J Respir Cell Mol Biol 2012, 47:50-59.
144. Limper AH Tumor necrosis factor alpha-mediated host defense against Pneumocystis carinii. Am J Respir Cell Mol Biol 1997, 16:110-111.
145. Chen W, Havell EA, Moldawer LL, et al. Interleukin 1: an important mediator of host resistance against Pneumocystis carinii. J Exp Med 1992, 176:713-718.
146. Chen W, Havell EA, Gigliotti F, Harmsen AG Interleukin-6 production in a murine model of Pneumocystis carinii pneumonia: relation to resistance and inflammatory response. Infect Immun 1993, 61:97-102.
147. Beck JM, Liggitt HD, Brunette EN, et al. Reduction in intensity of Pneumocystis carinii pneumonia in mice by aerosol administration of gamma interferon. Infect Immun 1991, 59:3859-3862.
148. Paine R, Preston AM, Wilcoxen S, et al. Granulocyte-macrophage colony-stimulating factor in the innate immune response to Pneumocystis carinii pneumonia in mice. J Immunol 2000, 164:2602-2609.
149. Ruan S, McKinley L, Zheng M, et al. Interleukin-12 and host defense against murine Pneumocystis pneumonia. Infect Immun 2008, 76:2130-2137.
150. Rudner XL, Happel KI, Young EA, et al. Interleukin-23 (IL-23)-IL-17 cytokine axis in murine Pneumocystis carinii infection. Infect Immun 2007, 75:3055-3061.
151. Qureshi MH, Harmsen AG, Garvy BA IL-10 modulates host responses and lung damage induced by Pneumocystis carinii infection. J Immunol 2003, 170:1002-1009.
152. Ieki R, Furuta T, Asano S, et al. Effect of recombinant human granulocyte colony-stimulating factor on Pneumocystis carinii infection in nude mice. Jpn J Exp Med 1989, 59:51-58.
153. Wright TW, Johnston CJ, Harmsen AG, Finkelstein JN Analysis of cytokine mRNA profiles in the lungs of Pneumocystis carinii-infected mice. Am J Respir Cell Mol Biol 1997, 17:491-500.
154. Perenboom RM, Beckers P, Van Der Meer JW, et al. Pro-inflammatory cytokines in lung and blood during steroid-induced Pneumocystis carinii pneumonia in rats. J Leukoc Biol 1996, 60:710-715.
155. Perenboom RM, van Schijndel AC, Beckers P, et al. Cytokine profiles in bronchoalveolar lavage fluid and blood in HIV-seronegative patients with Pneumocystis carinii pneumonia. Eur J Clin Invest 1996, 26:159-166.
156. Perenboom RM, Sauerwein RW, Beckers P, et al. Cytokine profiles in bronchoalveolar lavage fluid and blood in HIV-seropositive patients with Pneumocystis carinii pneumonia. Eur J Clin Invest 1997, 27:333-339.
157. Travis WD, Pittaluga S, Lipschik GY, et al. Atypical pathologic manifestations of Pneumocystis carinii pneumonia in the acquired immune deficiency syndrome. Review of 123 lung biopsies from 76 patients with emphasis on cysts, vascular invasion, vasculitis, and granulomas. Am J Surg Pathol 1990, 14:615-625.
158. Benfield TL, Prento P, Junge J, et al. Alveolar damage in AIDS-related Pneumocystis carinii pneumonia. Chest 1997, 111:1193-1199.
159. D'Angelo E, Calderini E, Robatto FM, et al. Lung and chest wall mechanics in patients with acquired immunodeficiency syndrome and severe Pneumocystis carinii pneumonia. Eur Respir J 1997, 10:2343-2350.
160. Stansell JD, Osmond DH, Charlebois E, et al. Predictors of Pneumocystis carinii pneumonia in HIV-infected persons. Pulmonary Complications of HIV Infection Study Group. Am J Respir Crit Care Med 1997, 155:60-66.
161. Wang Z, Foye A, Chang Y, et al. Inhibition of surfactant activity by Pneumocystis carinii organisms and components in vitro. Am J Physiol Lung Cell Mol Physiol 2005, 288:L1124-L1131.
162. Su TH, Natarajan V, Kachel DL, et al. Functional impairment of bronchoalveolar lavage phospholipids in early Pneumocystis carinii pneumonia in rats. J Lab Clin Med 1996, 127:263-271.
163. Hoffman AG, Lawrence MG, Ognibene FP, et al. Reduction of pulmonary surfactant in patients with human immunodeficiency virus infection and Pneumocystis carinii pneumonia. Chest 1992, 102:1730-1736.
164. Lipschik GY, Treml JF, Moore SD, Beers MF Pneumocystis carinii glycoprotein A inhibits surfactant phospholipid secretion by rat alveolar type II cells. J Infect Dis 1998, 177:182-187.
165. Sternberg RI, Whitsett JA, Hull WM, Baughman RP Pneumocystis carinii alters surfactant protein A concentrations in bronchoalveolar lavage fluid. J Lab Clin Med 1995, 125:462-469.
166. Beers MF, Atochina EN, Preston AM, Beck JM Inhibition of lung surfactant protein B expression during Pneumocystis carinii pneumonia in mice. J Lab Clin Med 1999, 133:423-433.
167. Atochina EN, Beck JM, Scanlon ST, et al. Pneumocystis carinii pneumonia alters expression and distribution of lung collectins SP-A and SP-D. J Lab Clin Med 2001, 137:429-439.
168. + T cells into severe combined immunodeficiency mice. J Clin Invest 1992, 90:673-678.
169. Wright TW, Gigliotti F, Finkelstein JN, et al. Immune-mediated inflammation directly impairs pulmonary function, contributing to the pathogenesis of Pneumocystis carinii pneumonia. J Clin Invest 1999, 104:1307-1317.
170. Wright TW, Johnston CJ, Harmsen AG, Finkelstein JN Chemokine gene expression during Pneumocystis carinii-driven pulmonary inflammation. Infect Immun 1999, 67:3452-3460.
171. Wright TW, Notter RH, Wang Z, et al. Pulmonary inflammation disrupts surfactant function during Pneumocystis carinii pneumonia. Infect Immun 2001, 69:758-764.
172. Bhagwat SP, Gigliotti F, Xu H, Wright TW Contribution of T cell subsets to the pathophysiology of Pneumocystis-related immunorestitution disease. Am J Physiol Lung Cell Mol Physiol 2006, 291:L1256-L1266.
173. + T cell-mediated pulmonary hyperinflammation driven by Pneumocystis carinii in immunodeficient mice. Eur J Immunol 2002, 32:1282-1291.
174. Gigliotti F, Crow EL, Bhagwat SP, Wright TW Sensitized CD8+ T cells fail to control organism burden but accelerate the onset of lung injury during Pneumocystis carinii pneumonia. Infect Immun 2006, 74:6310-6316.
175. Meissner NN, Lund FE, Han S, Harmsen A CD8 T cell-mediated lung damage in response to the extracellular pathogen pneumocystis is dependent on MHC class I expression by radiation-resistant lung cells. J Immunol 2005, 175:8271-8279.
176. McKinley L, Logar AJ, McAllister F, et al. Regulatory T cells dampen pulmonary inflammation and lung injury in an animal model of Pneumocystis pneumonia. J Immunol 2006, 177:6215-6226.
177. Swain SD, Meissner NN, Harmsen AG CD8 T cells modulate CD4 T-cell and eosinophil-mediated pulmonary pathology in Pneumocystis pneumonia in B-cell-deficient mice. Am J Pathol 2006, 168:466-475.
178. Swain SD, Wright TW, Degel PM, et al. Neither neutrophils nor reactive oxygen species contribute to tissue damage during Pneumocystis pneumonia in mice. Infect Immun 2004, 72:5722-5732.
179. Thullen TD, Ashbaugh AD, Daly KR, et al. Sensitized splenocytes result in deleterious cytokine cascade and hyperinflammatory response in rats with Pneumocystis pneumonia despite the presence of corticosteroids. Infect Immun 2004, 72:757-765.
180. Mason GR, Hashimoto CH, Dickman PS, et al. Prognostic implications of bronchoalveolar lavage neutrophilia in patients with Pneumocystis carinii pneumonia and AIDS. Am Rev Respir Dis 1989, 139:1336-1342.
181. Benfield TL, Vestbo J, Junge J, et al. Prognostic value of interleukin-8 in AIDS-associated Pneumocystis carinii pneumonia. Am J Respir Crit Care Med 1995, 151:1058-1062.
182. Benfield TL, Kharazmi A, Larsen CG, Lundgren JD Neutrophil chemotactic activity in bronchoalveolar lavage fluid of patients with AIDS-associated Pneumocystis carinii pneumonia. Scand J Infect Dis 1997, 29:367-371.
183. Benfield TL, Lundgren B, Levine SJ, et al. The major surface glycoprotein of Pneumocystis carinii induces release and gene expression of interleukin-8 and tumor necrosis factor alpha in monocytes. Infect Immun 1997, 65:4790-4794.
184. Tachado SD, Zhang J, Zhu J, et al. Pneumocystis-mediated IL-8 release by macrophages requires coexpression of mannose receptors and TLR2. J Leukoc Biol 2007, 81:205-211.
185. Consensus statement on the use of corticosteroids as adjunctive therapy for pneumocystis pneumonia in the acquired immunodeficiency syndrome. The National Institutes of Health-University of California Expert Panel for Corticosteroids as Adjunctive Therapy for Pneumocystis Pneumonia. N Engl J Med 1990, 323:1500-1504.
186. Benfield TL, van Steenwijk R, Nielsen TL, et al. Interleukin-8 and eicosanoid production in the lung during moderate to severe Pneumocystis carinii pneumonia in AIDS: a role of interleukin-8 in the pathogenesis of P. carinii pneumonia. Respir Med 1995, 89:285-290.
187. Huang ZB, Eden E Effect of corticosteroids on IL1 beta and TNF alpha release by alveolar macrophages from patients with AIDS and Pneumocystis carinii pneumonia. Chest 1993, 104:751-755.
188. Benfield TL, Schattenkerk JK, Hofmann B, et al. Differential effect on serum neopterin and serum beta 2-microglobulin is induced by treatment in Pneumocystis carinii pneumonia. J Infect Dis 1994, 169:1170-1173.
189. Dichter JR, Lundgren JD, Nielsen TL, et al. Pneumocystis carinii pneumonia in HIV-infected patients: effect of steroid therapy on surfactant level. Respir Med 1999, 93:373-378.
190. Zar HJ Pneumonia in HIV-infected and HIV-uninfected children in developing countries: epidemiology, clinical features, and management. Curr Opin Pulm Med 2004, 10:176-182.
191. Huang L Clinical presentation and diagnosis of Pneumocystis pneumonia in HIV-infected patients. Pneumocystis pneumonia 2005, 349-406. Marcell Dekker, New York. P.D. Walzer, M.T. Cushion (Eds.).
192. Haverkos HW Assessment of therapy for Pneumocystis carinii pneumonia. PCP Therapy Project Group. Am J Med 1984, 76:501-508.
193. Kovacs JA, Hiemenz JW, Macher AM, et al. Pneumocystis carinii pneumonia: a comparison between patients with the acquired immunodeficiency syndrome and patients with other immunodeficiencies. Ann Intern Med 1984, 100:663-671.
194. Chen HX, Ryan PA, Ferguson RP, et al. Characteristics of acquired immunodeficiency syndrome in older adults. J Am Geriatr Soc 1998, 46:153-156.
195. Laing R, Brettle R, Leen C, Hulks G Features and outcome of Pneumocystis carinii pneumonia according to risk category for HIV infection. Scand J Infect Dis 1997, 29:57-61.
196. Fahy JV, Chin DP, Schnapp LM, et al. Effect of aerosolized pentamidine prophylaxis on the clinical severity and diagnosis of Pneumocystis carinii pneumonia. Am Rev Respir Dis 1992, 146:844-848.
197. Tumeh SS, Belville JS, Pugatch R, McNeil BJ Ga-67 scintigraphy and computed tomography in the diagnosis of Pneumocystis carinii pneumonia in patients with AIDS. A prospective comparison. Clin Nucl Med 1992, 17:387-394.
198. Goldenberg DM, Sharkey RM, Udem S, et al. Immunoscintigraphy of Pneumocystis carinii pneumonia in AIDS patients. J Nucl Med 1994, 35:1028-1034.
199. Benson CA, Spear J, Hines D, et al. Combined APACHE II score and serum lactate dehydrogenase as predictors of in-hospital mortality caused by first episode Pneumocystis carinii pneumonia in patients with acquired immunodeficiency syndrome. Am Rev Respir Dis 1991, 144:319-323.
200. Ng VL, Yajko DM, Hadley WK Extrapulmonary pneumocystosis. Clin Microbiol Rev 1997, 10:401-418.
201. Murdoch DM, Venter WD, Van Rie A, Feldman C Immune reconstitution inflammatory syndrome (IRIS): review of common infectious manifestations and treatment options. AIDS Res Ther 2007, 4:9.
202. Ratnam I, Chiu C, Kandala NB, Easterbrook PJ Incidence and risk factors for immune reconstitution inflammatory syndrome in an ethnically diverse HIV type 1-infected cohort. Clin Infect Dis 2006, 42:418-427.
203. Hirsch HH, Kaufmann G, Sendi P, Battegay M Immune reconstitution in HIV-infected patients. Clin Infect Dis 2004, 38:1159-1166.
204. Takahashi T, Nakamura T, Iwamoto A Reconstitution of immune responses to Pneumocystis carinii pneumonia in patients with HIV infection who receive highly active antiretroviral therapy. Res Commun Mol Pathol Pharmacol 2002, 112:59-67.
205. Gruden JF, Huang L, Turner J, et al. High-resolution CT in the evaluation of clinically suspected Pneumocystis carinii pneumonia in AIDS patients with normal, equivocal, or nonspecific radiographic findings. AJR Am J Roentgenol 1997, 169:967-975.
206. Huang L, Stansell J, Osmond D, et al. Performance of an algorithm to detect Pneumocystis carinii pneumonia in symptomatic HIV-infected persons. Pulmonary Complications of HIV Infection Study Group. Chest 1999, 115:1025-1032.
207. Montaner J, Zala C The role of the laboratory in the diagnosis and management of AIDS-related Pneumocystis carinii pneumonia. Pneumocystis carinii 1995, 471-485. Bailliere Tindall, London. F. Sattler, P.D. Walzer (Eds.).
208. Kroe DM, Kirsch CM, Jensen WA Diagnostic strategies for Pneumocystis carinii pneumonia. Semin Respir Infect 1997, 12:70-78.
209. Aslanzadeh J, Stelmach PS Detection of Pneumocystis carinii with direct fluorescence antibody and calcofluor white stain. Infection 1996, 24:248-250.
210. Smulian AG, Linke MJ, Cushion MT, et al. Analysis of Pneumocystis carinii organism burden, viability and antigens in bronchoalveolar lavage fluid in AIDS patients with pneumocystosis: correlation with disease severity. AIDS 1994, 8:1555-1562.
211. Huggett JF, Taylor MS, Kocjan G, et al. Development and evaluation of a real-time PCR assay for detection of Pneumocystis jirovecii DNA in bronchoalveolar lavage fluid of HIV-infected patients. Thorax 2008, 63:154-159.
212. Robberts FJ, Liebowitz LD, Chalkley LJ Polymerase chain reaction detection of Pneumocystis jiroveci: evaluation of 9 assays. Diagn Microbiol Infect Dis 2007, 58:385-392.
213. Alvarez-Martinez MJ, Miro JM, Valls ME, et al. Sensitivity and specificity of nested and real-time PCR for the detection of Pneumocystis jiroveci in clinical specimens. Diagn Microbiol Infect Dis 2006, 56:153-160.
214. Birriel JA, Adams JA, Saldana MA, et al. Role of flexible bronchoscopy and bronchoalveolar lavage in the diagnosis of pediatric acquired immunodeficiency syndrome-related pulmonary disease. Pediatrics 1991, 87:897-899.
215. Helweg-Larsen J Pneumocystis jiroveci. Applied molecular microbiology, epidemiology and diagnosis. Dan Med Bull 2004, 51:251-273.
216. Miller RF, Huang L A need for standardized definitions for clinical studies of Pneumocystis. J Eukaryot Microbiol 2006, 53(suppl 1):S87-S88.
217. Cadranel J, Gillet-Juvin K, Antoine M, et al. Site-directed bronchoalveolar lavage and transbronchial biopsy in HIV-infected patients with pneumonia. Am J Respir Crit Care Med 1995, 152:1103-1106.
218. Huang L, Hecht FM, Stansell JD, et al. Suspected Pneumocystis carinii pneumonia with a negative induced sputum examination. Is early bronchoscopy useful?. Am J Respir Crit Care Med 1995, 151:1866-1871.
219. Skelly MJ, Holzman RS, Merali S S-adenosylmethionine levels in the diagnosis of Pneumocystis carinii pneumonia in patients with HIV infection. Clin Infect Dis 2008, 46:467-471.
220. de Boer MG, Gelinck LB, van Zelst BD, et al. β-d-glucan and S-adenosylmethionine serum levels for the diagnosis of Pneumocystis pneumonia in HIV-negative patients: a prospective study. J Infect 2011, 62:93-100.
221. Karageorgopoulos DE, Qu JM, Korbila IP, et al. Accuracy of beta-d-glucan for the diagnosis of Pneumocystis jirovecii pneumonia: a meta-analysis. Clin Microbiol Infect 2013, 19:39-49.
222. Bennett CL, Curtis JR, Achenbach C, et al. U.S. hospital care for HIV-infected persons and the role of public, private, and Veterans Administration hospitals. J Acquir Immune Defic Syndr Hum Retrovirol 1996, 13:416-421.
223. Curtis JR, Ullman M, Collier AC, et al. Variations in medical care for HIV-related Pneumocystis carinii pneumonia: a comparison of process and outcome at two hospitals. Chest 1997, 112:398-405.
224. Masur H, Shelhamer J Empiric outpatient management of HIV-related pneumonia: economical or unwise?. Ann Intern Med 1996, 124:451-453.
225. Glassroth J Empiric diagnosis of Pneumocystis carinii pneumonia. Questions of accuracy and equity. Am J Respir Crit Care Med 1995, 152:1433-1434.
226. Parada JP, Deloria-Knoll M, Chmiel JS, et al. Relationship between health insurance and medical care for patients hospitalized with human immunodeficiency virus-related Pneumocystis carinii pneumonia, 1995-1997: Medicaid, bronchoscopy, and survival. Clin Infect Dis 2003, 37:1549-1555.
227. Gracia JD, Miravitlles M, Mayordomo C, et al. Empiric treatments impair the diagnostic yield of BAL in HIV-positive patients. Chest 1997, 111:1180-1186.
228. Walzer PD, Evans HE, Copas AJ, et al. Early predictors of mortality from Pneumocystis jirovecii pneumonia in HIV-infected patients: 1985-2006. Clin Infect Dis 2008, 46:625-633.
229. Fei MW, Kim EJ, Sant CA, et al. Predicting mortality from HIV-associated Pneumocystis pneumonia at illness presentation: an observational cohort study. Thorax 2009, 64:1070-1076.
230. Monnet X, Vidal-Petiot E, Osman D, et al. Critical care management and outcome of severe Pneumocystis pneumonia in patients with and without HIV infection. Crit Care 2008, 12:R28.
231. Li MC, Lee NY, Lee CC, et al. Pneumocystis jiroveci pneumonia in immunocompromised patients: delayed diagnosis and poor outcomes in non-HIV-infected individuals. J Microbiol Immunol Infect 2012.
232. Rabodonirina M, Vaillant L, Taffe P, et al. Pneumocystis jirovecii genotype associated with increased death rate of HIV-infected patients with pneumonia. Emerg Infect Dis 2013, 19:21-28.
233. Keely SP, Stringer JR, Baughman RP, et al. Genetic variation among Pneumocystis carinii hominis isolates in recurrent pneumocystosis. J Infect Dis 1995, 172:595-598.
234. Dohn MN, Baughman RP, Vigdorth EM, Frame DL Equal survival rates for first, second, and third episodes of Pneumocystis carinii pneumonia in patients with acquired immunodeficiency syndrome. Arch Intern Med 1992, 152:2465-2470.
235. Metersky ML, Colt HG, Olson LK, Shanks TG AIDS-related spontaneous pneumothorax. Risk factors and treatment. Chest 1995, 108:946-951.
236. Stansell JD, Hopewell PC Pneumocystis carinii pneumonia: risk factors, clinical presentation and natural history. Pneumocystis carinii 1995, 449-459. Bailliere Tindall, London. F.R. Sattler, P.D. Walzer (Eds.).
237. Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents: Recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America Available at, Accessed April 16, 2014. http://aidsinfo.nih.gov/contentfiles/adult_oi.pdf.
238. Hughes WT, Feldman S, Chaudhary SC, et al. Comparison of pentamidine isethionate and trimethoprim-sulfamethoxazole in the treatment of Pneumocystis carinii pneumonia. J Pediatr 1978, 92:285-291.
239. Wharton JM, Coleman DL, Wofsy CB, et al. Trimethoprim-sulfamethoxazole or pentamidine for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A prospective randomized trial. Ann Intern Med 1986, 105:37-44.
240. Sattler FR, Cowan R, Nielsen DM, Ruskin J Trimethoprim-sulfamethoxazole compared with pentamidine for treatment of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A prospective, noncrossover study. Ann Intern Med 1988, 109:280-287.
241. Klein NC, Duncanson FP, Lenox TH, et al. Trimethoprim-sulfamethoxazole versus pentamidine for Pneumocystis carinii pneumonia in AIDS patients: results of a large prospective randomized treatment trial. AIDS 1992, 6:301-305.
242. Larsen HH, Masur H, Kovacs JA Current regimens for treatment and prophylaxis of Pneumocystis jirovecii pneumonia. Pneumocystis pneumonia 2005, 505-538. Marcel Dekker, New York. P.D. Walzer, M.T. Cushion (Eds.).
243. Stein DS, Stevens RC Treatment-associated toxicities: incidence and mechanisms. Pneumocystis carinii 1995, 505-530. Baillliere Tindall, London. F.R. Sattler, P.D. Walzer (Eds.).
244. Carr A, Swanson C, Penny R, Cooper DA Clinical and laboratory markers of hypersensitivity to trimethoprim-sulfamethoxazole in patients with Pneumocystis carinii pneumonia and AIDS. J Infect Dis 1993, 167:180-185.
245. Veenstra J, Veugelers PJ, Keet IP, et al. Rapid disease progression in human immunodeficiency virus type 1-infected individuals with adverse reactions to trimethoprim-sulfamethoxazole prophylaxis. Clin Infect Dis 1997, 24:936-941.
246. Velazquez H, Perazella MA, Wright FS, Ellison DH Renal mechanism of trimethoprim-induced hyperkalemia. Ann Intern Med 1993, 119:296-301.
247. Joos B, Blaser J, Opravil M, et al. Monitoring of co-trimoxazole concentrations in serum during treatment of Pneumocystis carinii pneumonia. Antimicrob Agents Chemother 1995, 39:2661-2666.
248. Caumes E, Roudier C, Rogeaux O, et al. Effect of corticosteroids on the incidence of adverse cutaneous reactions to trimethoprim-sulfamethoxazole during treatment of AIDS-associated Pneumocystis carinii pneumonia. Clin Infect Dis 1994, 18:319-323.
249. Leoung GS, Stanford JF, Giordano MF, et al. Trimethoprim-sulfamethoxazole (TMP-SMZ) dose escalation versus direct rechallenge for Pneumocystis carinii pneumonia prophylaxis in human immunodeficiency virus-infected patients with previous adverse reaction to TMP-SMZ. J Infect Dis 2001, 184:992-997.
250. Safrin S, Finkelstein DM, Feinberg J, et al. Comparison of three regimens for treatment of mild to moderate Pneumocystis carinii pneumonia in patients with AIDS. A double-blind, randomized, trial of oral trimethoprim-sulfamethoxazole, dapsone-trimethoprim, and clindamycin-primaquine. ACTG 108 Study Group. Ann Intern Med 1996, 124:792-802.
251. Lee BL, Medina I, Benowitz NL, et al. Dapsone, trimethoprim, and sulfamethoxazole plasma levels during treatment of Pneumocystis pneumonia in patients with the acquired immunodeficiency syndrome (AIDS). Evidence of drug interactions. Ann Intern Med 1989, 110:606-611.
252. Toma E, Fournier S, Dumont M, et al. Clindamycin/primaquine versus trimethoprim-sulfamethoxazole as primary therapy for Pneumocystis carinii pneumonia in AIDS: a randomized, double-blind pilot trial. Clin Infect Dis 1993, 17:178-184.
253. Hughes W, Leoung G, Kramer F, et al. Comparison of atovaquone (566C80) with trimethoprim-sulfamethoxazole to treat Pneumocystis carinii pneumonia in patients with AIDS. N Engl J Med 1993, 328:1521-1527.
254. Dohn MN, Weinberg WG, Torres RA, et al. Oral atovaquone compared with intravenous pentamidine for Pneumocystis carinii pneumonia in patients with AIDS. Atovaquone Study Group. Ann Intern Med 1994, 121:174-180.
255. Rosenberg DM, McCarthy W, Slavinsky J, et al. Atovaquone suspension for treatment of Pneumocystis carinii pneumonia in HIV-infected patients. AIDS 2001, 15:211-214.
256. Benfield T, Atzori C, Miller RF, Helweg-Larsen J Second-line salvage treatment of AIDS-associated Pneumocystis jirovecii pneumonia: a case series and systematic review. J Acquir Immune Defic Syndr 2008, 48:63-67.
257. Smego RA, Nagar S, Maloba B, Popara M A meta-analysis of salvage therapy for Pneumocystis carinii pneumonia. Arch Intern Med 2001, 161:1529-1533.
258. Black JR, Feinberg J, Murphy RL, et al. Clindamycin and primaquine therapy for mild-to-moderate episodes of Pneumocystis carinii pneumonia in patients with AIDS: AIDS Clinical Trials Group 044. Clin Infect Dis 1994, 18:905-913.
259. Noskin GA, Murphy RL, Black JR, Phair JP Salvage therapy with clindamycin/primaquine for Pneumocystis carinii pneumonia. Clin Infect Dis 1992, 14:183-188.
260. Comtois R, Pouliot J, Vinet B, et al. Higher pentamidine levels in AIDS patients with hypoglycemia and azotemia during treatment of Pneumocystis carinii pneumonia. Am Rev Respir Dis 1992, 146:740-744.
261. Sattler FR, Jelliffe RW Pharmacokinetic and pharmacodynamic considerations for drug dosing in the treatment of Pneumocystis carinii pneumonia. Pneumocystis carinii Pneumonia 1994, 467-486. Marcel Dekker, New York. P.D. Walzer (Ed.).
262. Lidman C, Bronner U, Gustafsson LL, Rombo L Plasma pentamidine concentrations vary between individuals with Pneumocystis carinii pneumonia and the drug is actively secreted by the kidney. J Antimicrob Chemother 1994, 33:803-810.
263. Kleyman TR, Roberts C, Ling BN A mechanism for pentamidine-induced hyperkalemia: inhibition of distal nephron sodium transport. Ann Intern Med 1995, 122:103-106.
264. Briel M, Bucher HC, Boscacci R, Furrer H Adjunctive corticosteroids for Pneumocystis jiroveci pneumonia in patients with HIV-infection. Cochrane Database Syst Rev 2006, (3).
265. Bozzette SA, Morton SC Reconsidering the use of adjunctive corticosteroids in Pneumocystis pneumonia?. J Acquir Immune Defic Syndr Hum Retrovirol 1995, 8:345-347.
266. Walmsley S, Levinton C, Brunton J, et al. A multicenter randomized double-blind placebo-controlled trial of adjunctive corticosteroids in the treatment of Pneumocystis carinii pneumonia complicating the acquired immune deficiency syndrome. J Acquir Immune Defic Syndr Hum Retrovirol 1995, 8:348-357.
267. Kazanjian P, Armstrong W, Hossler PA, et al. Pneumocystis carinii mutations are associated with duration of sulfa or sulfone prophylaxis exposure in AIDS patients. J Infect Dis 2000, 182:551-557.
268. Stein CR, Poole C, Kazanjian P, Meshnick SR Sulfa use, dihydropteroate synthase mutations, and Pneumocystis jirovecii pneumonia. Emerg Infect Dis 2004, 10:1760-1765.
269. Crothers K, Beard CB, Turner J, et al. Severity and outcome of HIV-associated Pneumocystis pneumonia containing Pneumocystis jirovecii dihydropteroate synthase gene mutations. AIDS 2005, 19:801-805.
270. Valerio A, Tronconi E, Mazza F, et al. Genotyping of Pneumocystis jiroveci pneumonia in Italian AIDS patients. Clinical outcome is influenced by dihydropteroate synthase and not by internal transcribed spacer genotype. J Acquir Immune Defic Syndr 2007, 45:521-528.
271. Alvarez-Martinez MJ, Moreno A, Miro JM, et al. Pneumocystis jirovecii pneumonia in Spanish HIV-infected patients in the combined antiretroviral therapy era: prevalence of dihydropteroate synthase mutations and prognostic factors of mortality. Diagn Microbiol Infect Dis 2008, 62:34-43.
272. Kazanjian P, Armstrong W, Hossler PA, et al. Pneumocystis carinii cytochrome b mutations are associated with atovaquone exposure in patients with AIDS. J Infect Dis 2001, 183:819-822.
273. Struijk GH, Gijsen AF, Yong SL, et al. Risk of Pneumocystis jiroveci pneumonia in patients long after renal transplantation. Nephrol Dial Transplant 2011, 26:3391-3398.
274. Cheng CY, Chen MY, Hsieh SM, et al. Risk of pneumocystosis after early discontinuation of prophylaxis among HIV-infected patients receiving highly active antiretroviral therapy. BMC Infect Dis 2010, 10:126.
275. Mocroft A, Reiss P, Kirk O, et al. Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count <200 cells/microL?. Clin Infect Dis 2010, 51:611-619.
276. D'Egidio GE, Kravcik S, Cooper CL, et al. Pneumocystis jiroveci pneumonia prophylaxis is not required with a CD4+ T-cell count < 200 cells/microl when viral replication is suppressed. AIDS 2007, 21:1711-1715.
277. Green H, Paul M, Vidal L, Leibovici L Prophylaxis of Pneumocystis pneumonia in immunocompromised non-HIV-infected patients: systematic review and meta-analysis of randomized controlled trials. Mayo Clin Proc 2007, 82:1052-1059.
278. Green H, Paul M, Vidal L, Leibovici L Prophylaxis for Pneumocystis pneumonia (PCP) in non-HIV immunocompromised patients. Cochrane Database Syst Rev 2007, (3).
279. Wang J, Wright TW, Gigliotti F Immune modulation as adjunctive therapy for Pneumocystis pneumonia. Interdiscip Perspect Infect Dis 2011, 2011:918038.
280. Bhagwat SP, Wright TW, Gigliotti F Anti-CD3 antibody decreases inflammation and improves outcome in a murine model of Pneumocystis pneumonia. J Immunol 2010, 184:497-502.
281. Le Gal S, Damiani C, Rouille A, et al. A cluster of Pneumocystis infections among renal transplant recipients: molecular evidence of colonized patients as potential infectious sources of Pneumocystis jirovecii. Clin Infect Dis 2012, 54:e62-e71.
282. Coyle PV, McCaughey C, Nager A, et al. Rising incidence of Pneumocystis jirovecii pneumonia suggests iatrogenic exposure of immune-compromised patients may be becoming a significant problem. J Med Microbiol 2012, 61:1009-1015.
283. Kaneshiro ES, Maiorano JN Survival and infectivity of Pneumocystis carinii outside the mammalian host. J Eukaryot Microbiol 1996, 43:35S.
284. Kuramochi T, Hioki K, Ito M Pneumocystis carinii cysts are susceptible to inactivation by chemical disinfectants. Exp Anim 1997, 46:241-245.
285. Cisse OH, Pagni M, Hauser PM De novo assembly of the Pneumocystis jirovecii genome from a single bronchoalveolar lavage fluid specimen from a patient. MBio 2012, 4:e00428-e00512.
286. Redhead SA, Cushion MT, Frenkel JK, Stringer JR Pneumocystis and Trypanosoma cruzi: nomenclature and typifications. J Eukaryot Microbiol 2006, 53:2-11.
287. Cushion MT, Collins MS Susceptibility of Pneumocystis to echinocandins in suspension and biofilm cultures. Antimicrob Agents Chemother 2011, 55:4513-4518.
288. Cushion MT, Linke MJ, Ashbaugh A, et al. Echinocandin treatment of Pneumocystis pneumonia in rodent models depletes cysts leaving trophic burdens that cannot transmit the infection. PLoS One 2010, 5:e8524.
289. Kaneshiro ES Sterol metabolism in the opportunistic pathogen Pneumocystis: advances and new insights. Lipids 2004, 39:753-761.
290. Hauser PM, Burdet FX, Cisse OH, et al. Comparative genomics suggests that the fungal pathogen pneumocystis is an obligate parasite scavenging amino acids from its host's lungs. PLoS One 2010, 5:e15152.
291. De Stefano JA, Myers JD, Du Pont D, et al. Cell wall antigens of Pneumocystis carinii trophozoites and cysts: purification and carbohydrate analysis of these glycoproteins. J Eukaryot Microbiol 1998, 45:334-343.
292. Porollo A, Meller J, Joshi Y, et al. Analysis of current antifungal agents and their targets within the Pneumocystis carinii genome. Curr Drug Targets 2012, 13:1575-1585.
293. Stringer JR Antigenic variation in pneumocystis. J Eukaryot Microbiol 2007, 54:8-13.
294. Gigliotti F, Hughes WT Passive immunoprophylaxis with specific monoclonal antibody confers partial protection against Pneumocystis carinii pneumonitis in animal models. J Clin Invest 1988, 81:1666-1668.
295. Theus SA, Smulian AG, Steele P, et al. Immunization with the major surface glycoprotein of Pneumocystis carinii elicits a protective response. Vaccine 1998, 16:1149-1157.
296. Ezekowitz RA, Williams DJ, Koziel H, et al. Uptake of Pneumocystis carinii mediated by the macrophage mannose receptor. Nature 1991, 351:155-158.
297. O'Riordan DM, Standing JE, Kwon KY, et al. Surfactant protein D interacts with Pneumocystis carinii and mediates organism adherence to alveolar macrophages. J Clin Invest 1995, 95:2699-2710.
298. Kutty G, Ma L, Kovacs JA Characterization of the expression site of the major surface glycoprotein of human-derived Pneumocystis carinii. Mol Microbiol 2001, 42:183-193.
299. Walzer PD, Djawe K, Levin L, et al. Long-term serologic responses to the Pneumocystis jirovecii major surface glycoprotein in HIV-positive individuals with and without P. jirovecii infection. J Infect Dis 2009, 199:1335-1344.
300. Tipirneni R, Daly KR, Jarlsberg LG, et al. Healthcare worker occupation and immune response to Pneumocystis jirovecii. Emerg Infect Dis 2009, 15:1590-1597.
301. Schaffzin JK, Sunkin SM, Stringer JR A new family of Pneumocystis carinii genes related to those encoding the major surface glycoprotein. Curr Genet 1999, 35:134-143.
302. Montes-Cano MA, Chabe M, Fontillon-Alberdi M, et al. Vertical transmission of Pneumocystis jirovecii in humans. Emerg Infect Dis 2009, 15:125-127.
303. Vargas SL, Hughes WT, Santolaya ME, et al. Search for primary infection by Pneumocystis carinii in a cohort of normal, healthy infants. Clin Infect Dis 2001, 32:855-861.
304. Larsen HH, von Linstow ML, Lundgren B, et al. Primary Pneumocystis infection in infants hospitalized with acute respiratory tract infection. Emerg Infect Dis 2007, 13:66-72.
305. Vargas SL, Ponce CA, Luchsinger V, et al. Detection of Pneumocystis carinii f. sp. hominis and viruses in presumably immunocompetent infants who died in the hospital or in the community. J Infect Dis 2005, 191:122-126.
306. Davis JL, Welsh DA, Beard CB, et al. Pneumocystis colonisation is common among hospitalised HIV infected patients with non-Pneumocystis pneumonia. Thorax 2008, 63:329-334.
307. Shipley TW, Kling HM, Morris, et al. Persistent Pneumocystis colonization leads to the development of chronic obstructive pulmonary disease in a non human primate model of AIDS. J Infect Dis 2010, 202:302-312.
308. Masur H, Michelis MA, Greene JB, et al. An outbreak of community-acquired Pneumocystis carinii pneumonia: initial manifestation of cellular immune dysfunction. N Engl J Med 1981, 305:1431-1438.
309. de Boer MG, Kroon FP, le Cessie S, et al. Risk factors for Pneumocystis jirovecii pneumonia in kidney transplant recipients and appraisal of strategies for selective use of chemoprophylaxis. Transpl Infect Dis 2011, 13:559-569.
310. Dohn MN, White ML, Vigdorth EM, et al. Geographic clustering of Pneumocystis carinii pneumonia in patients with HIV infection. Am J Respir Crit Care Med 2000, 162:1617-1621.
311. Morris AM, Swanson M, Ha H, Huang L Geographic distribution of human immunodeficiency virus-associated Pneumocystis carinii pneumonia in San Francisco. Am J Respir Crit Care Med 2000, 162:1622-1626.
312. Miller RF, Evans HE, Copas AJ, Cassell JA Climate and genotypes of Pneumocystis jirovecii. Clin Microbiol Infect 2007, 13:445-448.
313. Djawe K, Levin L, Swartzman A, et al. Environmental risk factors for Pneumocystis pneumonia hospitalizations in HIV patients. Clin Infect Dis 2013, 56:74-81.
314. Icenhour CR, Rebholz SL, Collins MS, Cushion MT Widespread occurrence of Pneumocystis carinii in commercial rat colonies detected using targeted PCR and oral swabs. J Clin Microbiol 2001, 39:3437-3441.
315. de Boer MG, de Fijter JW, Kroon FP Outbreaks and clustering of Pneumocystis pneumonia in kidney transplant recipients: a systematic review. Med Mycol 2011, 49:673-680.
316. Choukri F, Menotti J, Sarfati C, et al. Quantification and spread of Pneumocystis jirovecii in the surrounding air of patients with Pneumocystis pneumonia. Clin Infect Dis 2010, 51:259-265.
317. Gingo MR, Lucht L, Daly KR, et al. Serologic responses to pneumocystis proteins in HIV patients with and without Pneumocystis jirovecii pneumonia. J Acquir Immune Defic Syndr 2011, 57:190-196.
318. Koziel H, Kim S, Reardon C, et al. Enhanced in vivo human immunodeficiency virus-1 replication in the lungs of human immunodeficiency virus-infected persons with Pneumocystis carinii pneumonia. Am J Respir Crit Care Med 1999, 160:2048-2055.
319. Limper AH, Edens M, Anders RA, Leof EB Pneumocystis carinii inhibits cyclin-dependent kinase activity in lung epithelial cells. J Clin Invest 1998, 101:1148-1155.
320. Linke MJ, Harris CE, Korfhagen TR, et al. Immunosuppressed surfactant protein A-deficient mice have increased susceptibility to Pneumocystis carinii infection. J Infect Dis 2001, 183:943-952.
321. Rapaka RR, Ricks DM, Alcorn JF, et al. Conserved natural IgM antibodies mediate innate and adaptive immunity against the opportunistic fungus Pneumocystis murina. J Exp Med 2010, 207:2907-2919.
322. Kling HM, Shipley TW, Patil SP, et al. Relationship of Pneumocystis jiroveci humoral immunity to prevention of colonization and chronic obstructive pulmonary disease in a primate model of HIV infection. Infect Immun 2010, 78:4320-4330.
323. Garvy BA, Wiley JA, Gigliotti F, Harmsen AG Protection against Pneumocystis carinii pneumonia by antibodies generated from either T helper 1 or T helper 2 responses. Infect Immun 1997, 65:5052-5056.
324. Zheng M, Ramsay AJ, Robichaux MB, et al. CD4+ T cell-independent DNA vaccination against opportunistic infections. J Clin Invest 2005, 115:3536-3544.
325. Zheng M, Rapaka RR, Yu AC, et al. Role of interleukin-23-dependent antifungal immune responses in dendritic cell-vaccinated mice. Infect Immun 2011, 79:3778-3783.
326. Jalil A, Moja P, Lambert C, et al. Decreased production of local immunoglobulin A to Pneumocystis carinii in bronchoalveolar lavage fluid from human immunodeficiency virus-positive patients. Infect Immun 2000, 68:1054-1060.
327. Shellito J, Suzara VV, Blumenfeld W, et al. A new model of Pneumocystis carinii infection in mice selectively depleted of helper T lymphocytes. J Clin Invest 1990, 85:1686-1693.
328. Theus SA, Andrews RP, Steele P, Walzer PD Adoptive transfer of lymphocytes sensitized to the major surface glycoprotein of Pneumocystis carinii confers protection in the rat. J Clin Invest 1995, 95:2587-2593.
329. Harmsen AG, Stankiewicz M Requirement for CD4+ cells in resistance to Pneumocystis carinii pneumonia in mice. J Exp Med 1990, 172:937-945.
330. Wiley JA, Harmsen AG CD40 ligand is required for resolution of Pneumocystis carinii pneumonia in mice. J Immunol 1995, 155:3525-3529.
331. Beck JM, Blackmon MB, Rose CM, et al. T cell costimulatory molecule function determines susceptibility to infection with Pneumocystis carinii in mice. J Immunol 2003, 171:1969-1977.
332. Qureshi MH, Garvy BA Neonatal T cells in an adult lung environment are competent to resolve Pneumocystis carinii pneumonia. J Immunol 2001, 166:5704-5711.
333. Phair J, Munoz A, Detels R, et al. The risk of Pneumocystis carinii pneumonia among men infected with human immunodeficiency virus type 1. Multicenter AIDS Cohort Study Group. N Engl J Med 1990, 322:161-165.
334. Iriart X, Witkowski B, Cassaing S, et al. Alveolar and blood T lymphocyte profiles in Pneumocystis jirovecii-positive patients: effects of HIV status. J Infect Dis 2011, 204:544-553.
335. Limper AH, Hoyte JS, Standing JE The role of alveolar macrophages in Pneumocystis carinii degradation and clearance from the lung. J Clin Invest 1997, 99:2110-2117.
336. Steele C, Marrero L, Swain S, et al. Alveolar macrophage-mediated killing of Pneumocystis carinii f. sp. muris involves molecular recognition by the Dectin-1 beta-glucan receptor. J Exp Med 2003, 198:1677-1688.
337. Vassallo R, Kottom TJ, Standing JE, Limper AH Vitronectin and fibronectin function as glucan binding proteins augmenting macrophage responses to Pneumocystis carinii. Am J Respir Cell Mol Biol 2001, 25:203-211.
338. Lasbury ME, Merali S, Durant PJ, et al. Polyamine-mediated apoptosis of alveolar macrophages during Pneumocystis pneumonia. J Biol Chem 2007, 282:11009-11020.
339. Kurkjian C, Hollifield M, Lines JL, et al. Alveolar macrophages in neonatal mice are inherently unresponsive to Pneumocystis murina infection. Infect Immun 2012, 80:2835-2846.
340. Inoue M, Moriwaki Y, Arikawa T, et al. Cutting edge: critical role of intracellular osteopontin in antifungal innate immune responses. J Immunol 2011, 186:19-23.
341. Koziel H, Eichbaum Q, Kruskal BA, et al. Reduced binding and phagocytosis of Pneumocystis carinii by alveolar macrophages from persons infected with HIV-1 correlates with mannose receptor downregulation. J Clin Invest 1998, 102:1332-1344.
342. Evans SE, Kottom TJ, Pagano RE, Limper AH Primary alveolar epithelial cell surface membrane microdomain function is required for Pneumocystis beta-glucan-induced inflammatory responses. Innate Immun 2012, 18:709-716.
343. Carmona EM, Kottom TJ, Hebrink DM, et al. Glycosphingolipids mediate pneumocystis cell wall beta-glucan activation of the IL-23/IL-17 axis in human dendritic cells. Am J Respir Cell Mol Biol 2012, 47:50-59.
344. Paine R, Preston AM, Wilcoxen S, et al. Granulocyte-macrophage colony-stimulating factor in the innate immune response to Pneumocystis carinii pneumonia in mice. J Immunol 2000, 164:2602-2609.
345. Rudner XL, Happel KI, Young EA, et al. Interleukin-23 (IL-23)-IL-17 cytokine axis in murine Pneumocystis carinii infection. Infect Immun 2007, 75:3055-3061.
346. Travis WD, Pittaluga S, Lipschik GY, et al. Atypical pathologic manifestations of Pneumocystis carinii pneumonia in the acquired immune deficiency syndrome. Review of 123 lung biopsies from 76 patients with emphasis on cysts, vascular invasion, vasculitis, and granulomas. Am J Surg Pathol 1990, 14:615-625.
347. D'Angelo E, Calderini E, Robatto FM, et al. Lung and chest wall mechanics in patients with acquired immunodeficiency syndrome and severe Pneumocystis carinii pneumonia. Eur Respir J 1997, 10:2343-2350.
348. Stansell JD, Osmond DH, Charlebois E, et al. Predictors of Pneumocystis carinii pneumonia in HIV-infected persons. Pulmonary Complications of HIV Infection Study Group. Am J Respir Crit Care Med 1997, 155:60-66.
349. Wang Z, Foye A, Chang Y, et al. Inhibition of surfactant activity by Pneumocystis carinii organisms and components in vitro. Am J Physiol Lung Cell Mol Physiol 2005, 288:L1124-L1131.
350. Atochina EN, Beck JM, Scanlon ST, et al. Pneumocystis carinii pneumonia alters expression and distribution of lung collectins SP-A and SP-D. J Lab Clin Med 2001, 137:429-439.
351. Wright TW, Gigliotti F, Finkelstein JN, et al. Immune-mediated inflammation directly impairs pulmonary function, contributing to the pathogenesis of Pneumocystis carinii pneumonia. J Clin Invest 1999, 104:1307-1317.
352. Wright TW, Notter RH, Wang Z, et al. Pulmonary inflammation disrupts surfactant function during Pneumocystis carinii pneumonia. Infect Immun 2001, 69:758-764.
353. McKinley L, Logar AJ, McAllister F, et al. Regulatory T cells dampen pulmonary inflammation and lung injury in an animal model of Pneumocystis pneumonia. J Immunol 2006, 177:6215-6226.
354. Mason GR, Hashimoto CH, Dickman PS, et al. Prognostic implications of bronchoalveolar lavage neutrophilia in patients with Pneumocystis carinii pneumonia and AIDS. Am Rev Respir Dis 1989, 139:1336-1342.
355. Benfield TL, Vestbo J, Junge J, et al. Prognostic value of interleukin-8 in AIDS-associated Pneumocystis carinii pneumonia. Am J Respir Crit Care Med 1995, 151:1058-1062.
356. Benfield TL, Lundgren B, Levine SJ, et al. The major surface glycoprotein of Pneumocystis carinii induces release and gene expression of interleukin-8 and tumor necrosis factor alpha in monocytes. Infect Immun 1997, 65:4790-4794.
357. Consensus statement on the use of corticosteroids as adjunctive therapy for pneumocystis pneumonia in the acquired immunodeficiency syndrome. The National Institutes of Health-University of California Expert Panel for Corticosteroids as Adjunctive Therapy for Pneumocystis Pneumonia. N Engl J Med 1990, 323:1500-1504.
358. Kovacs JA, Hiemenz JW, Macher AM, et al. Pneumocystis carinii pneumonia: a comparison between patients with the acquired immunodeficiency syndrome and patients with other immunodeficiencies. Ann Intern Med 1984, 100:663-671.
359. Fahy JV, Chin DP, Schnapp LM, et al. Effect of aerosolized pentamidine prophylaxis on the clinical severity and diagnosis of Pneumocystis carinii pneumonia. Am Rev Respir Dis 1992, 146:844-848.
360. Benson CA, Spear J, Hines D, et al. Combined APACHE II score and serum lactate dehydrogenase as predictors of in-hospital mortality caused by first episode Pneumocystis carinii pneumonia in patients with acquired immunodeficiency syndrome. Am Rev Respir Dis 1991, 144:319-323.
361. Takahashi T, Nakamura T, Iwamoto A Reconstitution of immune responses to Pneumocystis carinii pneumonia in patients with HIV infection who receive highly active antiretroviral therapy. Res Commun Mol Pathol Pharmacol 2002, 112:59-67.
362. Huang L, Stansell J, Osmond D, et al. Performance of an algorithm to detect Pneumocystis carinii pneumonia in symptomatic HIV-infected persons. Pulmonary Complications of HIV Infection Study Group. Chest 1999, 115:1025-1032.
363. Huggett JF, Taylor MS, Kocjan G, et al. Development and evaluation of a real-time PCR assay for detection of Pneumocystis jirovecii DNA in bronchoalveolar lavage fluid of HIV-infected patients. Thorax 2008, 63:154-159.
364. Alvarez-Martinez MJ, Miro JM, Valls ME, et al. Sensitivity and specificity of nested and real-time PCR for the detection of Pneumocystis jiroveci in clinical specimens. Diagn Microbiol Infect Dis 2006, 56:153-160.
365. Huang L, Hecht FM, Stansell JD, et al. Suspected Pneumocystis carinii pneumonia with a negative induced sputum examination. Is early bronchoscopy useful?. Am J Respir Crit Care Med 1995, 151:1866-1871.
366. Karageorgopoulos DE, Qu JM, Korbila IP, et al. Accuracy of beta-d-glucan for the diagnosis of Pneumocystis jirovecii pneumonia: a meta-analysis. Clin Microbiol Infect 2013, 19:39-49.
367. Walzer PD, Evans HE, Copas AJ, et al. Early predictors of mortality from Pneumocystis jirovecii pneumonia in HIV-infected patients: 1985-2006. Clin Infect Dis 2008, 46:625-633.
368. Fei MW, Kim EJ, Sant CA, et al. Predicting mortality from HIV-associated Pneumocystis pneumonia at illness presentation: an observational cohort study. Thorax 2009, 64:1070-1076.
369. Li MC, Lee NY, Lee CC, et al. Pneumocystis jiroveci pneumonia in immunocompromised patients: delayed diagnosis and poor outcomes in non-HIV-infected individuals. J Microbiol Immunol Infect 2012.
370. Rabodonirina M, Vaillant L, Taffe P, et al. Pneumocystis jirovecii genotype associated with increased death rate of HIV-infected patients with pneumonia. Emerg Infect Dis 2013, 19:21-28.
371. Metersky ML, Colt HG, Olson LK, Shanks TG AIDS-related spontaneous pneumothorax. Risk factors and treatment. Chest 1995, 108:946-951.
372. Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents Guidelines for the Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents: Recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America Available at, Accessed April 16, 2014. http://aidsinfo.nih.gov/contentfiles/adult_oi.pdf.
373. Hughes WT, Feldman S, Chaudhary SC, et al. Comparison of pentamidine isethionate and trimethoprim-sulfamethoxazole in the treatment of Pneumocystis carinii pneumonia. J Pediatr 1978, 92:285-291.
374. Sattler FR, Cowan R, Nielsen DM, Ruskin J Trimethoprim-sulfamethoxazole compared with pentamidine for treatment of Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. A prospective, noncrossover study. Ann Intern Med 1988, 109:280-287.
375. Carr A, Swanson C, Penny R, Cooper DA Clinical and laboratory markers of hypersensitivity to trimethoprim-sulfamethoxazole in patients with Pneumocystis carinii pneumonia and AIDS. J Infect Dis 1993, 167:180-185.
376. Velazquez H, Perazella MA, Wright FS, Ellison DH Renal mechanism of trimethoprim-induced hyperkalemia. Ann Intern Med 1993, 119:296-301.
377. Leoung GS, Stanford JF, Giordano MF, et al. Trimethoprim-sulfamethoxazole (TMP-SMZ) dose escalation versus direct rechallenge for Pneumocystis carinii pneumonia prophylaxis in human immunodeficiency virus-infected patients with previous adverse reaction to TMP-SMZ. J Infect Dis 2001, 184:992-997.
378. Safrin S, Finkelstein DM, Feinberg J, et al. Comparison of three regimens for treatment of mild to moderate Pneumocystis carinii pneumonia in patients with AIDS. A double-blind, randomized, trial of oral trimethoprim-sulfamethoxazole, dapsone-trimethoprim, and clindamycin-primaquine. ACTG 108 Study Group. Ann Intern Med 1996, 124:792-802.
379. Smego RA, Nagar S, Maloba B, Popara M A meta-analysis of salvage therapy for Pneumocystis carinii pneumonia. Arch Intern Med 2001, 161:1529-1533.
380. Briel M, Bucher HC, Boscacci R, Furrer H Adjunctive corticosteroids for Pneumocystis jiroveci pneumonia in patients with HIV-infection. Cochrane Database Syst Rev 2006, (3).
381. Walmsley S, Levinton C, Brunton J, et al. A multicenter randomized double-blind placebo-controlled trial of adjunctive corticosteroids in the treatment of Pneumocystis carinii pneumonia complicating the acquired immune deficiency syndrome. J Acquir Immune Defic Syndr Hum Retrovirol 1995, 8:348-357.
382. Stein CR, Poole C, Kazanjian P, Meshnick SR Sulfa use, dihydropteroate synthase mutations, and Pneumocystis jirovecii pneumonia. Emerg Infect Dis 2004, 10:1760-1765.
383. Kazanjian P, Armstrong W, Hossler PA, et al. Pneumocystis carinii cytochrome b mutations are associated with atovaquone exposure in patients with AIDS. J Infect Dis 2001, 183:819-822.
384. D'Egidio GE, Kravcik S, Cooper CL, et al. Pneumocystis jiroveci pneumonia prophylaxis is not required with a CD4+ T-cell count < 200 cells/microl when viral replication is suppressed. AIDS 2007, 21:1711-1715.
385. Bhagwat SP, Wright TW, Gigliotti F Anti-CD3 antibody decreases inflammation and improves outcome in a murine model of Pneumocystis pneumonia. J Immunol 2010, 184:497-502.
386. Le Gal S, Damiani C, Rouille A, et al. A cluster of Pneumocystis infections among renal transplant recipients: molecular evidence of colonized patients as potential infectious sources of Pneumocystis jirovecii. Clin Infect Dis 2012, 54:e62-e71.
387. Kuramochi T, Hioki K, Ito M Pneumocystis carinii cysts are susceptible to inactivation by chemical disinfectants. Exp Anim 1997, 46:241-245.